Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

In This Article:

Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc.
  • Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21st International Congress of the Society of Melanoma Research in October

  • Presenting initial results from the company-sponsored Phase 1/2a study of [212Pb]VMT-α-NET in patients with RPT-naïve neuroendocrine tumors at the upcoming 2024 North American Neuroendocrine Tumor Society Symposium in November

  • Shipping of investigational product started in October from a second manufacturing facility in Somerset, New Jersey; additional facility expansion activities ongoing

  • On track to advance multiple pre-IND assets into the clinic in the next 9-18 months

  • Cash, cash equivalents, and short-term investments balance of approximately $268 million expected to be sufficient to fund our current planned operations and capital investments into mid-2026

SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced third quarter financial results for the period ended September 30, 2024.

“Since our team initiated dosing of U.S. patients in two clinical programs in 2023, important learnings on each of these two clinical-stage constructs and the applicability of our proprietary radiopharmaceutical platform in a variety of clinical settings have informed our strategy to bring innovative precision medicines to patients based on alpha-emitting isotopes and targeting moiety optimization,” said Thijs Spoor, Perspective’s CEO. “At the time same, we continue to invest in developing proprietary compounds and building out a network of regional manufacturing sites to service treatment centers and patients, which currently consists of two active sites as well as three buildings being modified in anticipation of delivery of equipment already on order. We look forward to continued progress in the coming months and in 2025.”

Program Highlights
VMT-α-NET

Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET
We are conducting a multi-center open-label dose escalation, dose expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). We received Fast Track Designation for this program from the U.S. Food and Drug Administration (FDA) based on preclinical data for SSTR2-positive NETs regardless of prior treatment response.

Waiting for permission
Allow microphone access to enable voice search

Try again.